Who are Matched-Placebo for Tafenoquine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chloroquine profilaxis, amodiaquine+artesunate/artemether-lumefantrine, CQ coadministered with PQ, Tafenoquine prophylaxis, Supervised primaquine treatment, PQ supervised.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/matched-placebo-for-tafenoquine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Matched-Placebo for Tafenoquine — Competitive Intelligence Brief

Matched-Placebo for Tafenoquine (Matched-Placebo for Tafenoquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 8-aminoquinoline. Area: Infectious Diseases.

phase 3 8-aminoquinoline Plasmodium heme detoxification pathway Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Matched-Placebo for Tafenoquine (Matched-Placebo for Tafenoquine) — GlaxoSmithKline. Tafenoquine is an antimalarial drug that works by targeting the parasite's heme detoxification pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Matched-Placebo for Tafenoquine TARGET	Matched-Placebo for Tafenoquine	GlaxoSmithKline	phase 3	8-aminoquinoline	Plasmodium heme detoxification pathway
Chloroquine profilaxis	Chloroquine profilaxis	Institut de Recherche pour le Developpement	marketed	Quinoline antimalarial	Plasmodium heme detoxification pathway; DNA/RNA synthesis
amodiaquine+artesunate/artemether-lumefantrine	amodiaquine+artesunate/artemether-lumefantrine	University of Ghana Medical School	phase 3	Antimalarial	Plasmodium heme detoxification pathway
CQ coadministered with PQ	CQ coadministered with PQ	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	phase 3	Antimalarial combination	Plasmodium heme detoxification pathway; hypnozoite elimination
Tafenoquine prophylaxis	Tafenoquine prophylaxis	Naval Medical Research Center	marketed	8-aminoquinoline antimalarial	Plasmodium mitochondrial electron transport chain
Supervised primaquine treatment	Supervised primaquine treatment	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium parasite mitochondria and DNA
PQ supervised	PQ supervised	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium hypnozoites (mechanism not fully elucidated at molecular level)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (8-aminoquinoline class)

GlaxoSmithKline · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
State University of New York - Upstate Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Matched-Placebo for Tafenoquine — Competitive Intelligence Brief. https://druglandscape.com/ci/matched-placebo-for-tafenoquine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab